乳腺癌中的免疫学与免疫疗法

Immunology and immunotherapy in breast cancer.

作者信息

Semiglazov Vladimir, Tseluiko Andrey, Kudaybergenova Asel, Artemyeva Anna, Krivorotko Petr, Donskih Roman

机构信息

Petrov National Medicine Cancer-Research Center Ministry of Health, Saint-Petersburg 197758, Russia.

出版信息

Cancer Biol Med. 2022 Jun 9;19(5):609-18. doi: 10.20892/j.issn.2095-3941.2021.0597.

DOI:10.20892/j.issn.2095-3941.2021.0597

PMID:35676750

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9196061/

Abstract

Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials on various tumor types. In recent years, a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been developed. Breast cancer had been examined in the field of immune-oncology relatively recently. This review focuses on clinical evidence regarding immune checkpoint inhibition for curative treatment of various breast cancer subtypes. In addition, we present the results of studies demonstrating the prognostic and predictive value of levels of tumorinfiltrating lymphocytes (CD4 and CD8), their quantitative ratios, and their correlation with regulatory genes (PD-1, PD-L1, and FOX-P3).

摘要

免疫肿瘤学是医学中一个快速发展的领域。药物联合疗法已在针对各种肿瘤类型的许多临床试验中进行了研究。近年来，已经开发出了针对程序性死亡受体1（PD-1）及其配体程序性死亡配体1（PD-L1）的单克隆抗体的检查点抑制疗法。乳腺癌在免疫肿瘤学领域的研究相对较新。本综述重点关注关于免疫检查点抑制用于各种乳腺癌亚型根治性治疗的临床证据。此外，我们还展示了一些研究结果，这些结果证明了肿瘤浸润淋巴细胞（CD4和CD8）水平、它们的定量比率以及它们与调节基因（PD-1、PD-L1和叉头框蛋白P3）的相关性的预后和预测价值。